Publication:

Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing

Loading...
Thumbnail Image

Open/View Files

Date

2014

Published Version

Journal Title

Journal ISSN

Volume Title

Publisher

The Harvard community has made this article openly available. Please share how this access benefits you.

Research Projects

Organizational Units

Journal Issue

Citation

Heckl, Dirk, Monika S. Kowalczyk, David Yudovich, Roger Belizaire, Rishi V. Puram, Marie E. McConkey, Anne Thielke, Jon C. Aster, Aviv Regev, and Benjamin L. Ebert. 2014. “Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing.” Nature biotechnology 32 (9): 941-946. doi:10.1038/nbt.2951. http://dx.doi.org/10.1038/nbt.2951.

Abstract

Genome sequencing studies have shown that human malignancies often bear mutations in four or more driver genes1, but it is difficult to recapitulate this degree of genetic complexity in mouse models using conventional breeding. Here we use the CRISPR-Cas9 system of genome editing2–4 to overcome this limitation. By delivering combinations of small guide RNAs (sgRNAs) and Cas9 with a lentiviral vector, we modified up to five genes in a single mouse hematopoietic stem cell (HSC), leading to clonal outgrowth and myeloid malignancy. We thereby generated models of acute myeloid leukemia (AML) with cooperating mutations in genes encoding epigenetic modifiers, transcription factors, and mediators of cytokine signaling, recapitulating the combinations of mutations observed in the human disease. Our results suggest that lentivirus-delivered sgRNA:Cas9 genome editing should be useful to engineer a broad array of in vivo cancer models that better reflect the complexity of human disease.

Description

Research Data

Keywords

Terms of Use

This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service

Endorsement

Review

Supplemented By

Related Stories

Story
Generation of mouse models of myeloid… : DASH Story 2015-08-25
I am currently taking time off after almost 20 years in Research and am mulling a change in specialization. Furthermore, my sister was just diagnosed with AML and I have become her advocate and advisor on her treatment options. Unfettered access to publications from the Harvard Community has been invaluable to me. In my experience, the free exchange of information and ideas is crucial for advances in academic research. This concept should extend to the general population. Breakthroughs in research are often at least partially serendipitous and often involve individuals that did not follow the traditional academic trajectory as I believe they are freer to question dogma since they were not boxed in by many of the academic training programs. Limiting access to often government funded research to the very people that provide the funding for the research not only seems dishonest, but, I contend it limits scientific advances.